Enfortumab Vedotin-ejfv: A First-in-Class Anti–Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma

Abstract

Objective:

To evaluate the pharmacology, pharmacokinetics, clinical efficacy, safety, dosing, cost, and clinical implications of enfortumab vedotin-ejfv (EV) in the treatment of locally advanced or metastatic urothelial carcinoma (UC).

Data Sources:

A literature search of PubMed (inception to August 2020) was conducted using the terms enfortumab, vedotin, Padcev, and Nectin. Data were also obtained from package inserts, meeting abstracts, and ongoing studies from ClinicalTrials.gov.

Study Selection and Data Extraction:

All relevant published articles, package inserts, and meeting abstracts evaluating EV for the treatment of UC were analyzed.

Data Synthesis:

Antibody-drug conjugates (ADCs) deliver potent cytotoxic agents using highly selective monoclonal antibodies. Targeting the near-universal expression of Nectin-4 on UC cells is a viable therapeutic strategy. In a pivotal phase II trial, EV demonstrated an overall response rate of 44%, and a median duration of response of 7.6 months. Estimated overall survival was 11.7 months with a median estimated progression-free survival of 5.6 months. Results were similar among difficult-to-treat patients, including those with liver metastases. Unique toxicity concerns with EV require careful consideration and monitoring.

Relevance to Patient Care and Clinical Practice:

EV, a first-in-class anti–Nectin-4 ADC, provides impressive response rates with manageable toxicities, making it a promising treatment option for patients with multiply relapsed or refractory UC.

Conclusion:

The US Food and Drug Administration–approved EV demonstrates antitumor activity in heavily pretreated patients with UC but harbors important adverse effects and financial concerns. Additional studies are required to identify the optimal sequencing, patient population, and place in therapy for EV.

Keywords

antibody-drug conjugate urothelial carcinoma bladder cancer Nectin-4 enfortumab vedotin MMAE

Get full access to this article

View all access options for this article.

References

National Cancer Institute. Cancer stat fact: bladder cancer. Accessed August 10, 2020. https://seer.cancer.gov/statfacts/html/urinb.html

Grignon

. The current classification of urothelial neoplasms. Mod Pathol. 2009;22(suppl 2):S60-S69. doi:10.1038/modpathol.2008.235

National Comprehensive Cancer Network. Bladder cancer (version 5.2020). Accessed August 10, 2020. https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf

Powles

Durán

van der Heijden

, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018;391:748-757. doi:10.1016/S0140-6736(17)33297-X

Patel

Ellerton

Infante

, et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol. 2018;19:51-64. doi:10.1016/S1470-2045(17)30900-2

Powles

O’Donnell

Massard

, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study. JAMA Oncol. 2017;3:e172411. doi:10.1001/jamaoncol.2017.2411

Sharma

Retz

Siefker-Radtke

, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18:312-322. doi:10.1016/S1470-2045(17)30065-7

Bellmunt

de Wit

Vaughn

, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376:1015-1026. doi:10.1056/NEJMoa1613683

Challita-Eid

Satpayev

Yang

, et al. Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res. 2016;76:3003-3013. doi:10.1158/0008-5472.CAN-15-1313

10.

PADCEV. Package insert. Seattle Genetics, Inc/Astellas Pharma, Inc; 2019.

11.

Moher

Liberati

Tetzlaff

, et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann Intern Med. 2009;151:264-269. doi:10.7326/0003-4819-151-4-200908180-00135

12.

Rikitake

Mandai

Takai

. The role of nectins in different types of cell-cell adhesion. J Cell Sci. 2012;125(pt 16):3713-3722. doi:10.1242/jcs.099572

13.

Samanta

Almo

. Nectin family of cell-adhesion molecules: structural and molecular aspects of function and specificity. Cell Mol Life Sci. 2015;72:645-658. doi:10.1007/s00018-014-1763-4

14.

Zhang

Shen

, et al. High expression of Nectin-4 is associated with unfavorable prognosis in gastric cancer. Oncol Lett. 2018;15:8789-8795. doi:10.3892/ol.2018.8365

15.

Lattanzio

Ghasemi

Brancati

, et al. Membranous Nectin-4 expression is a risk factor for distant relapse of T1-T2, N0 luminal–A early breast cancer. Oncogenesis. 2014;3:e118. doi:10.1038/oncsis.2014.32

16.

Takano

Ishikawa

Nishino

, et al. Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer. Cancer Res. 2009;69:6694-6703. doi:10.1158/0008-5472.CAN-09-0016

17.

Pavlova

Pallasch

Elia

, et al. A role for PVRL4-driven cell-cell interactions in tumorigenesis. Elife. 2013;2: e00358. doi:10.7554/eLife.00358

18.

Boylan

Buchanan

Manion

, et al. The expression of Nectin-4 on the surface of ovarian cancer cells alters their ability to adhere, migrate, aggregate, and proliferate. Oncotarget. 2017;8:9717-9738. doi:10.18632/oncotarget.14206

19.

Nishiwada

Sho

Yasuda

, et al. Nectin-4 expression contributes to tumor proliferation, angiogenesis and patient prognosis in human pancreatic cancer. J Exp Clin Cancer Res. 2015;34:30. doi:10.1186/s13046-015-0144-7

20.

Maderna

Leverett

. Recent advances in the development of new auristatins: structural modifications and applications in antibody drug conjugates. Mol Pharm. 2015;12:1798-1812. doi:10.1021/mp500762u

21.

Pitot

McElroy

Jr Reid

, et al. Phase I trial of dolastatin10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res. 1999;5:525-531.

22.

Madden

Tran

Beck

, et al. Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res. 2000;6:1293-1301.

23.

Patel

Keohan

Saif

, et al. Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy. Cancer. 2006;107:2881-2887. doi:10.1002/cncr.22334

24.

Shnyder

Cooper

Millington

Petti

Bibby

. Auristatin PYE, a novel synthetic derivative of dolastatin 10, is highly effective in human colon tumour models. Int J Oncol. 2007;31:353-360.

25.

Doronina

Toki

Torgov

, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003;21:778-784. doi:10.1038/nbt832

26.

Adcetris®. Package insert. Seattle Genetics Inc; 2014.

27.

Polivy™. Package insert. Genetech Inc; 2019.

28.

Han

Zhao

. Absorption, distribution, metabolism, and excretion considerations for the development of antibody-drug conjugates. Drug Metab Dispos. 2014;42:1914-1920. doi:10.1124/dmd.114.058586

29.

Rosenberg

Sridhar

Zhang

, et al. EV-101: a phase I study of single-agent enfortumab vedotin in patients with nectin-4-positive solid tumors, including metastatic urothelial carcinoma. J Clin Oncol. 2020;38:1041-1049. doi:10.1200/JCO.19.02044

30.

Rosenberg

O’Donnell

Balar

, et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy. J Clin Oncol. 2019;37:2592-2600. doi:10.1200/JCO.19.01140

31.

Rosenberg

Flaig

Friedlander

, et al. Study EV-103: preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma [abstract]. J Clin Oncol. 2020;20;38(6, suppl):441.

32.

Younes

Gopal

Smith

, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30:2183-2189. doi:10.1200/JCO.2011.38.0410

33.

Banerjee

Oza

Birrer

, et al. Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study. Ann Oncol. 2018;29:917-923. doi:10.1093/annonc/mdy023

34.

McGregor

O’Donnell

Balar

, et al. Quality of life of metastatic urothelial cancer (mUC) patients treated with enfortumab vedotin (EV) following platinum-containing chemotherapy and a checkpoint inhibitor (CPI): data from EV-201 cohort 1. Ann Oncol. 2019;30(suppl 5):v356-v402.

35.

Aaronson

Ahmedzai

Bergman

, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-376. doi:10.1093/jnci/85.5.365

36.

Rabin

de Charro

. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33:337-343. doi:10.3109/07853890109002087

37.

IBM Corporation. IBM Micromedex®. Accessed July 7, 2020. https://www.micromedexsolutions.com/micromedex2/librarian/CS/51E01A/ND_PR/evidencexpert/ND_P/evidencexpert/DUPLICATIONSHIELDSYNC/404BFD/ND_PG/evidencexpert/ND_B/evidencexpert/ND_AppProduct/evidencexpert/ND_T/evidencexpert/PFActionId/redbook.FindRedBook?navitem=topRedBook&isToolPage=true

38.

FiercePharma. Seattle Genetics, Astellas snag quick FDA approval for bladder cancer fighter Padcev. Published December 18, 2019. Accessed September 4, 2020. https://www.fiercepharma.com/pharma/seattle-genetics-astellas-snag-quick-fda-approval-for-bladder-cancer-fighter-padcev

39.

Loriot

Necchi

Park

, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019;381:338-348. doi:10.1056/NEJMoa1817323